Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–45
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Male healthy subjects and male asthma patients aged 18 to 45 years (inclusive)
Have a body mass index (BMI) between 18 and 30 kg/m2 (inclusive and rounding allowed) and weight between 50 and 100 kg (inclusive)
Be able to inhale from the SPIRA nebuliser and I-neb® according to the provided instructions
Asthma patients should fulfil the following criteria: Pre-bronchodilator forced expiratory volume at 1 second (FEV1) ≥70% of predicted normal value
Asthma diagnosis according to GINA guidelines with a history of episodic wheeze and shortness of breath
You may not be if
History of any clinically significant disease or disorder
Any clinically relevant abnormal findings
Current smokers
Asthma patients: Worsening of asthma or respiratory infection within 6 weeks before screening
Asthma patients: Use of inhaled, nasal, oral, rectal or parenteral corticosteroids within 30 days before first administration of investigational product and during the study
Clareo Health | A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways
